NCT06664515 is a clinical trial of Ciro Costagliola in Full Macular Hole, sponsored by Federico II University.

Who is sponsoring NCT06664515?

NCT06664515 is sponsored by Federico II University.

What drugs are being tested in NCT06664515?

Interventions in NCT06664515: Ciro Costagliola.

What condition does NCT06664515 study?

NCT06664515 studies Full Macular Hole.

Is NCT06664515 still recruiting?

NCT06664515 is currently completed. Last updated 1 November 2024.

Last reviewed 2024-11-01 · How we verify

NCT06664515

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Changes InMPOD After Full-thickness Macular Hole Closure

Completed Last updated 1 November 2024

What this trial tests

trial testing Ciro Costagliola in Full Macular Hole in 15 participants. Completed in 1 October 2024.

Timeline

1 June 2023

Primary endpoint
1 July 2023

1 October 2024

Quick facts

Lead sponsor	Federico II University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	15
Start date	1 June 2023
Primary completion	1 July 2023
Estimated completion	1 October 2024
Sites	1 location across Italy

Drugs / interventions tested

Ciro Costagliola

Conditions studied

Full Macular Hole — all drugs for Full Macular Hole →

Sponsor

Federico II University

Who can join

Eligibility, any sex, with Full Macular Hole. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The notable increase in MPOD following successful surgery suggests its potential role as a valuable adjunctive biomarker associated with a good visual prognosis following this type of macular hole surgical interventions.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Macular Pigment Changes and Visual Recovery Following Successful Full-Thickness Macular Hole Closure Using the Inverted Flap Technique.
Rinaldi M, Galantuomo N, Passaro ML, Cennamo G, et al · · 2025 · cited 1× · PMID 39797372 · DOI 10.3390/jcm14010290

Verify or expand the search:

Other Federico II University trials

Trials by the same sponsor.

NCT07437690 — Fall Prevention in Older Adults in an Italian Cohort · not yet recruiting
NCT07282132 — Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter · not yet recruiting
NCT07280286 — Incidence of Intrauterine Adhesions After Myomectomy With Intrauterine Anti-Adhesion Gel · NA · not yet recruiting
NCT07374861 — Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy · recruiting
NCT07314684 — GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06664515 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Federico II University
Last refreshed: 1 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06664515.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing